| Literature DB >> 30052888 |
Gregory Y H Lip1,2,3, Jean-Phillippe Collet4, Michael Haude5, Robert Byrne6,7, Eugene H Chung8, Laurent Fauchier9, Sigrun Halvorsen10, Dennis Lau11, Nestor Lopez-Cabanillas12, Maddalena Lettino13, Francisco Marin14, Israel Obel15, Andrea Rubboli16, Robert F Storey17, Marco Valgimigli18, Kurt Huber19.
Abstract
In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.Entities:
Year: 2019 PMID: 30052888 DOI: 10.1093/europace/euy174
Source DB: PubMed Journal: Europace ISSN: 1099-5129 Impact factor: 5.214